- Home
- LTBR vs LEXX Comparison
LTBR vs LEXX Comparison
Compare LTBR & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTBR
- LEXX
- Stock Information
- Founded
- LTBR 1992
- LEXX 2004
- Country
- LTBR United States
- LEXX Canada
- Employees
- LTBR N/A
- LEXX N/A
- Industry
- LTBR Professional Services
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- LTBR Consumer Discretionary
- LEXX Health Care
- Exchange
- LTBR Nasdaq
- LEXX Nasdaq
- Market Cap
- LTBR 45.5M
- LEXX 38.9M
- IPO Year
- LTBR N/A
- LEXX N/A
- Fundamental
- Price
- LTBR $4.66
- LEXX $2.23
- Analyst Decision
- LTBR
- LEXX Strong Buy
- Analyst Count
- LTBR 0
- LEXX 2
- Target Price
- LTBR N/A
- LEXX $11.00
- AVG Volume (30 Days)
- LTBR 963.8K
- LEXX 202.7K
- Earning Date
- LTBR 10-31-2024
- LEXX 01-10-2025
- Dividend Yield
- LTBR N/A
- LEXX N/A
- EPS Growth
- LTBR N/A
- LEXX N/A
- EPS
- LTBR N/A
- LEXX N/A
- Revenue
- LTBR N/A
- LEXX $464,278.00
- Revenue This Year
- LTBR N/A
- LEXX $20.39
- Revenue Next Year
- LTBR N/A
- LEXX $113.25
- P/E Ratio
- LTBR N/A
- LEXX N/A
- Revenue Growth
- LTBR N/A
- LEXX 105.24
- 52 Week Low
- LTBR $2.21
- LEXX $1.20
- 52 Week High
- LTBR $14.20
- LEXX $6.85
- Technical
- Relative Strength Index (RSI)
- LTBR 39.05
- LEXX 47.23
- Support Level
- LTBR $4.43
- LEXX $2.00
- Resistance Level
- LTBR $5.50
- LEXX $2.54
- Average True Range (ATR)
- LTBR 0.54
- LEXX 0.24
- MACD
- LTBR -0.10
- LEXX -0.00
- Stochastic Oscillator
- LTBR 15.68
- LEXX 27.06
About LTBR Lightbridge Corporation
Lightbridge Corp is a United States-based nuclear fuel technology company. The business activity of the firm is functioned through Nuclear Fuel Technology segment. The Nuclear Fuel Technology segment develops next generation nuclear fuel technology that increases the power output of commercial reactors and reduces the cost of generating electricity. Geographically, its operations are functioned through the region of Unites States.
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.